Copyright
©The Author(s) 2023.
World J Cardiol. Apr 26, 2023; 15(4): 142-153
Published online Apr 26, 2023. doi: 10.4330/wjc.v15.i4.142
Published online Apr 26, 2023. doi: 10.4330/wjc.v15.i4.142
Figure 1 Flow-chart for the management of antithrombotic therapy in patients with coronary artery disease.
CAD: Coronary artery disease; DAPT: Dual antiplatelet therapy; DM: Disease management; eGRF: Glomerular Filtration Rate; PAD: Peripheral arterial disease; MI: Myocardial infarction.
Figure 2 Antithrombotic strategies in patients with peripheral artery disease according to vascular guidelines.
PAD: Peripheral artery disease; CVD: Cardiovascular disease; CAD: Coronary artery disease.
Figure 3 Current indications to lipid-lowering drugs in patients with coronary and peripheral artery disease.
CVD: Cardiovascular disease; LDL-C: Low-density Lipoprotein Cholesterol; PCSK9: Proprotein convertase subtilisinkexin type 9; siRNA: Small interfering RNA.
- Citation: Gioscia R, Castagno C, Verdoia M, Conti B, Forliti E, Rognoni A. Optimization of the pharmacological therapy in patients with poly-vascular disease: A multidisciplinary approach. World J Cardiol 2023; 15(4): 142-153
- URL: https://www.wjgnet.com/1949-8462/full/v15/i4/142.htm
- DOI: https://dx.doi.org/10.4330/wjc.v15.i4.142